Genflow Biosciences PLC Announces Corporate Update
The grant application's initial rejection leaves financial guidance unchanged because Genflow had not assumed receipt of the funding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Genflow Biosciences (GENFF) received Japanese patent allowance for its SIRT6 gene therapy platform and signed additional animal health confidentiality agreements. The Japan Patent Office allowed all 16 claims covering SIRT6 variants for preventing or treating age-related diseases. The application is exclusively licensed to Genflow; registration remains subject to payment of the registration fee.
Additional animal health companies are evaluating the therapy for companion animals. An approximately EUR 0.76 million regional research grant application for an 18-month MASH research project was not approved at initial review. Genflow requested reopening of the file. The programme continues as planned, and financial guidance is unchanged because it did not assume the grant.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Moderate pointJapanese patent allowance covers all 16 claims for SIRT6 variants exclusively licensed to Genflow.
- Minor pointAdditional animal health companies signed confidentiality agreements to evaluate SIRT6 gene therapy for companion animals.
- Minor point. Forward-looking: it has not happened yet and may not happen.Genflow's MASH programme continues as planned despite the initial grant rejection.
Negative
- Moderate pointApproximately EUR 0.76 million research grant application was not approved at initial review; reopening requested.
- Minor pointJapanese patent registration remains subject to payment of the registration fee within the statutory 30-day period.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LONDON, UK / ACCESS Newswire / October 9, 2026 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF), a biotechnology company developing gene therapies targeting the biology of ageing, provides a corporate update.
Highlights
- Japan Patent Office issues Decision to Grant for a patent application covering SIRT6 variants for use in preventing and treating age-related diseases, with 16 allowed claims.
- Additional animal health companies have signed confidentiality agreements (CDAs) to evaluate Genflow's SIRT6 gene therapy, broadening the Company's partnering pipeline in veterinary medicine.
- Following the initial review of its regional research grant application, the Company has requested that the file be reopened and is working with the authority to advance the application. There is no expected impact on the Company's financial guidance.
Japanese Patent Allowance
The Japan Patent Office (JPO) has issued a Decision to Grant, the Japanese equivalent of a notice of allowance, for Japanese Patent Application No. 2024-515284. The application is titled "Variants of SIRT6 for use in preventing and/or treating age-related diseases." The JPO found no grounds for rejection and allowed all 16 claims. The decision was dated 15 September 2026 and dispatched on 24 September 2026.
The application is owned by the University of Rochester and co-applicants and is exclusively licensed to Genflow. It protects the SIRT6 variant at the core of Genflow's gene therapy platform. The patent will be registered upon payment of the registration fee, which the Company will make within the statutory 30-day period.
Japan is one of the world's largest pharmaceutical markets and has one of the oldest populations globally. This allowance strengthens Genflow's international intellectual property estate.
Expanded Animal Health Interest
Genflow has entered into confidentiality agreements (CDAs) with additional animal health companies. Each company is evaluating Genflow's SIRT6 gene therapy for use in companion animals.
The new agreements build on the Company's ongoing animal health discussions. Ageing-related conditions in dogs and cats represent a significant and growing market, driven by longer pet lifespans and rising spending on veterinary care. Veterinary development paths can also generate efficacy and safety data on shorter timelines than human studies.
Regional Grant Application
Genflow's Belgian subsidiary applied to the Walloon Region (Service public de Wallonie) for a research grant of approximately EUR 0.76 million. The grant would have been applied to the 18-month MASH research project. The Region's selection committee did not approve the application at the initial review stage.
Under the Region's rules, applicants may request that a file be reopened for review at a subsequent committee meeting. The request is being submitted The Company's MASH programme continues as planned.
The Company's financial guidance did not assume receipt of this grant. The decision has no impact on Genflow's financial guidance.
Dr Eric Leire, Chief Executive Officer of Genflow, said: "The allowance of our Japanese patent is an important step in building global protection for our SIRT6 platform in a market where healthy ageing is a national priority. At the same time, growing interest from animal health companies reflects the breadth of opportunity for our approach beyond human medicine. We look forward to advancing these discussions and to presenting new data in the months ahead."
Enquiries
Genflow Biosciences plc - Dr Eric Leire, CEO
On365 IR firm - ir@genflowbio.com
About Genflow Biosciences
Genflow Biosciences plc is a biotechnology company developing gene therapies that target the biology of ageing. Its lead platform is SIRT6c, a variant of the SIRT6 gene identified in centenarians. Genflow is developing SIRT6c across human indications using mRNA-LNP delivery, including metabolic dysfunction-associated steatohepatitis (MASH) and ophthalmology, and in a veterinary programme in ageing dogs. Genflow is listed on the London Stock Exchange (GENF) and quoted on the OTCQB (GENFF).
Forward-looking statements
The contents of this announcement have been prepared by, and are the sole responsibility of, the Company.
This announcement may contain forward-looking statements. The forward-looking statements include, but are not limited to, statements regarding the Company's or the Directors' expectations, hopes, beliefs, intentions or strategies regarding the future. In addition, any statement that refers to projections, forecasts or other characterisations of future events or circumstances, including any underlying assumptions, is a forward-looking statement. The words "anticipate", "believe", "continue", "could", "estimate", "expect", "intend", "may", "might", "plan", "possible", "potential", "predict", "project", "seek", "should", "would" and similar expressions, or in each case their negatives, may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.
Forward-looking statements include all matters that are not historical facts. Forward-looking statements are based on the current expectations and assumptions regarding the Company, the business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Forward-looking statements are not guarantees of future performance and the Company's actual financial condition, actual results of operations and financial performance, and the development of the industries in which it operates or will operate, may differ materially from those made in or suggested by the forward-looking statements contained in this announcement. In addition, even if the Company's financial condition, results of operations and the development of the industries in which it operates or will operate, are consistent with the forward-looking statements contained in this announcement, those results or developments may not be indicative of financial condition, results of operations or developments in subsequent periods. Important factors that could cause actual results to differ materially from those in the forward-looking statements include regional, national or global, political, economic, social, business, technological, competitive, market and regulatory conditions.
Any forward-looking statement contained in this announcement applies only as of the date of this announcement and is expressly qualified in its entirety by these cautionary statements. Factors or events that could cause the Company's actual plans or results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions or circumstances on which any forward-looking statement contained in this announcement is based, unless required to do so by applicable law, the Prospectus Regulation Rules, the Listing Rules, the Disclosure Guidance and Transparency Rules of the FCA or the UK Market Abuse Regulation.
END
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: Genflow Biosciences PLC
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Genflow's Japanese SIRT6 patent allowance cover?
The Japan Patent Office allowed all 16 claims covering SIRT6 variants for preventing or treating age-related diseases. The Decision to Grant concerned Japanese Patent Application No. 2024-515284 and was dated 15 September 2026.
Who owns the Japanese patent application licensed to Genflow?
The University of Rochester and co-applicants own the application, which is exclusively licensed to Genflow. It protects the SIRT6 variant at the core of the company's gene therapy platform.